Every research peptide contains impurities. Understanding what these impurities are, how they arise, and what they mean for your research enables informed decisions about peptide suitability. This guide covers the interpretation of Certificate of Analysis (COA) data and common impurity types.
The Certificate of Analysis
What a COA Should Include
**Essential Information:**
Peptide name and sequenceBatch/lot numberMolecular weight (theoretical and observed)Purity by HPLCMS data (identity confirmation)Net peptide contentAppearanceStorage recommendations**Desirable Additions:**
HPLC chromatogramMS spectrumAmino acid analysisCounterion informationEndotoxin levels (for in vivo use)Reading the HPLC Purity
**What "95% pure by HPLC" means:**
The main peak represents 95% of the integrated areaDetected impurities total 5%Detection is typically at 220 nm (peptide bond absorbance)Relative quantification (not absolute)**Limitations:**
Co-eluting impurities not resolvedResponse factors differ between peptidesMethod-dependent (gradient, column, etc.)Not all impurities detectedTypes of Impurities
Synthesis-Related Impurities
**Deletion Peptides:**
Missing one or more amino acidsResult from incomplete couplingMW = target - residue massOften difficult to separate from target**Example:**
Target: AGFLR (MW 559.7)
Missing Gly deletion: AFLR (MW 502.6)
Missing Phe deletion: AGLR (MW 412.5)
**Truncated Peptides:**
Synthesis terminated earlyUsually from chain terminationShorter sequencesMay be significant impurities**Insertion Peptides:**
Extra amino acid incorporatedLess common than deletionsMW = target + residue massModification-Related Impurities
**Oxidation Products:**
Methionine sulfoxide (+16 Da)Tryptophan oxidation productsCan form during synthesis, purification, or storageCheck MS for +16 Da peaks**Deamidation Products:**
Asn to Asp (+1 Da)Gln to Glu (+1 Da)Often seen as shoulder peaks on HPLCMay be functionally similar to target**Incomplete Protecting Group Removal:**
Residual protecting groupsVarious mass additionsShould be minimal with proper cleavageStereochemical Impurities
**Racemization:**
D-amino acid formationSame mass as targetMay have different retention timeCan affect biological activity**DKP (Diketopiperazine) Formation:**
Cyclization of dipeptideSeen with C-terminal Pro or GlyLoss of dipeptide from sequenceAggregation-Related
**Oligomers:**
Dimers, trimers of the peptideThrough disulfide bonds or hydrophobic interactionMW multiples of monomerMay elute at different retention timeInterpreting MS Data
Confirming Identity
**What to check:**
Observed mass matches expected (within instrument error)Typical mass accuracy: +/- 0.1% for standard MSAccount for charge states in ESIAccount for adducts**Common Mass Differences:**
DifferencePossible Cause
|------------|----------------|
+16Oxidation (Met, Trp)
+1Deamidation
-18Dehydration
+22Na adduct (instead of H+)
+38K adduct (instead of H+)
+42Acetylation
-residue massDeletion
Reading ESI-MS Spectra
For multiply charged ions:
[M+H]+ = singly charged[M+2H]2+ = doubly charged (mass/2 + 1)[M+3H]3+ = triply charged (mass/3 + 1)**Calculating true mass:**
M = (observed m/z x z) - (z x 1.008)
**Example:**
Observed: m/z 600.3, z=2M = (600.3 x 2) - (2 x 1.008) = 1198.6 DaIdentifying Unknown Peaks
When MS shows unexpected masses:
Calculate mass difference from targetCheck against common modifications listConsider loss or addition of amino acidsLook for counterion or adduct massesInterpreting HPLC Chromatograms
Main Peak Analysis
**Characteristics of good target peak:**
Symmetric shapeSharp, not broadDominant (according to purity specification)Single maximumImpurity Peak Analysis
**What to note:**
Relative retention time to main peakApproximate percentage (by area)Peak shape (sharp vs. broad)Pattern (related impurities often cluster)Common Patterns
**Early-Eluting Impurities:**
More polar than targetMay include: deamidated products, oxidized products, deletion peptides missing hydrophobic residueTruncated sequences often elute earlier**Late-Eluting Impurities:**
Less polar than targetMay include: protected sequences, deletion peptides missing polar residue, oligomersFatty acid-modified contamination**Shoulder Peaks:**
Close elution to main peakOften stereoisomers or single-residue modificationsMay indicate deamidation or isomerizationPractical Implications
Acceptable Impurity Levels
**Application-dependent guidance:**
ApplicationTypical Minimum Purity
|-------------|----------------------|
Initial screening75-85%
Biochemical assays90-95%
Cell-based assays95%+
In vivo studies95%+
Clinical research98%+
Reference standards99%+
When Impurities Matter Most
**Higher purity important when:**
Quantitative dose-response requiredImpurity could be activeLong-term stability neededRegulatory considerationsResults will be published**Impurities may be tolerable when:**
Qualitative screening onlyImpurities are inactiveShort-term useInternal use onlyImpurity Activity Considerations
**Potentially active impurities:**
Deletion peptides (may retain partial activity)Stereoisomers (may have different selectivity)Oxidized forms (may be inactive or differently active)**Typically inactive impurities:**
Significantly truncated sequencesPeptides missing critical residuesAggregates (often inaccessible)Requesting Additional Information
When to Ask Vendor
Request more data if:
COA seems incompleteNeed to identify specific impuritiesUnusual results suggest quality issueCritical application requires verificationWhat to Request
Full HPLC chromatogramMS spectrum showing isotope patternAmino acid analysisCounterion analysisEndotoxin dataQuality Verification
Independent Testing
Consider third-party analysis for:
Critical research projectsUnusual or unexpected resultsHigh-value experimentsWhen vendor data seems questionableFunctional Verification
Beyond analytical purity:
Test biological activityCompare to previous lotsInclude positive controlsVerify expected behaviorConclusion
Interpreting COA data empowers researchers to understand what they are actually working with beyond a simple purity percentage. Knowing the types of impurities present, their likely origins, and their potential impacts enables informed decisions about peptide suitability for specific applications. When in doubt, request additional data or consider independent verification for critical applications.